198 related articles for article (PubMed ID: 23810844)
1. Enrichment of IL-12-producing plasmacytoid dendritic cells in donor bone marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation.
Darlak KA; Wang Y; Li JM; Harris WA; Owens LM; Waller EK
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1331-9. PubMed ID: 23810844
[TBL] [Abstract][Full Text] [Related]
2. IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
Lu Y; Giver CR; Sharma A; Li JM; Darlak KA; Owens LM; Roback JD; Galipeau J; Waller EK
Blood; 2012 Jan; 119(4):1075-85. PubMed ID: 22130799
[TBL] [Abstract][Full Text] [Related]
3. Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes.
Hassan M; Ulezko Antonova A; Li JM; Hosoba S; Rupji M; Kowalski J; Perricone AJ; Jaye DL; Marsh H; Yellin M; Devine S; Waller EK
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1075-1084. PubMed ID: 30503387
[TBL] [Abstract][Full Text] [Related]
4. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
5. Transplantation of Graft Anti-Host Cytotoxic T Lymphocytes Along with Allogeneic Bone Marrow Skips Macrophage-Induced Graft-Versus-Host Disease.
Yoshida R; Yamana H; Hayashi M; Yasuda E; Shibayama Y; Hirose Y; Tanigawa N; Uchiyama K; Kubota T
J Interferon Cytokine Res; 2021 Sep; 41(9):310-318. PubMed ID: 34543129
[TBL] [Abstract][Full Text] [Related]
6. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
[TBL] [Abstract][Full Text] [Related]
7. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
8. Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation.
Li JM; Southerland LT; Lu Y; Darlak KA; Giver CR; McMillin DW; Harris WA; Jaye DL; Waller EK
J Immunol; 2009 Dec; 183(12):7799-809. PubMed ID: 19933853
[TBL] [Abstract][Full Text] [Related]
9. Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.
Waller EK; Logan BR; Harris WA; Devine SM; Porter DL; Mineishi S; McCarty JM; Gonzalez CE; Spitzer TR; Krijanovski OI; Linenberger ML; Woolfrey A; Howard A; Wu J; Confer DL; Anasetti C
J Clin Oncol; 2014 Aug; 32(22):2365-72. PubMed ID: 24982459
[TBL] [Abstract][Full Text] [Related]
10. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation.
Lim JY; Ryu DB; Lee SE; Park G; Choi EY; Min CK
Mol Cells; 2015 Nov; 38(11):966-74. PubMed ID: 26552489
[TBL] [Abstract][Full Text] [Related]
11. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
14. Flt-3L Expansion of Recipient CD8α
Markey KA; Kuns RD; Browne DJ; Gartlan KH; Robb RJ; Martins JP; Henden AS; Minnie SA; Cheong M; Koyama M; Smyth MJ; Steptoe RJ; Belz GT; Brocker T; Degli-Esposti MA; Lane SW; Hill GR
Clin Cancer Res; 2018 Apr; 24(7):1604-1616. PubMed ID: 29367429
[No Abstract] [Full Text] [Related]
15. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK
Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089
[TBL] [Abstract][Full Text] [Related]
16. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
17. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
18. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
19. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
20. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]